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Background: Metastatic melanoma involving the esophagus is rare; the occurrence of metastatic melanoma in a
background of Barrett esophagus is rarer still. We report a case of an 80 year-old male who presented to our
institution for workup of Barrett esophagus with high-grade dysplasia and who proved to have metastatic
melanoma occurring in the background of Barrett esophagus, the first report of this kind, to our knowledge, in the
English literature.
Case presentation: An 80 year-old Caucasian male was diagnosed at an outside institution with Barrett’s esophagus
with high grade dysplasia and presented to our institution for therapy. The patient underwent endoscopic
mucosal resection using a band ligation technique of an area of nodularity within the Barrett esophagus.
Microscopic examination demonstrated extensive Barrett esophagus with high-grade dysplasia as well as a second
tumor which was morphologically different from the surrounding high-grade dysplasia and which was positive for
S-100, HMB 45 and Melan-A on immunohistochemistry, consistent with melanoma. Further workup of the patient
demonstrated multiple radiologic lesions consistent with metastases. Molecular studies demonstrated that the
melanoma was positive for the 1799T>A (V600E) mutation in the BRAF gene. The overall features of the tumor
were most consistent with metastatic melanoma occurring in a background of Barrett esophagus with high-grade
dysplasia.
Conclusion: This case demonstrates a unique intersection between a premalignant condition (Barrett esophagus
with high grade dysplasia) and a separate malignancy (melanoma). This report also shows the utility of molecular
testing to support the hypothesis of primary versus metastatic disease in melanoma.
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Melanoma is the most common tumor that metastasizes
to the gastrointestinal tract, most frequently to the small
bowel, while primary melanoma occurs most frequently
in the anorectum, followed by the oral cavity, esophagus,
stomach, small bowel, gallbladder, and large bowel [1,2].
Despite this, both primary and metastatic melanoma of
the esophagus are rare entities with primary esophageal
melanoma accounting for less than 1% of all primary
esophageal malignancies and esophageal metastatic* Correspondence: dtrembat@unch.unc.edu
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metastatic to the gastrointestinal tract [2].
Barrett esophagus (BE) is a premalignant condition
characterized by the replacement of the usual squamous
epithelium of the distal esophagus by columnar-type
mucosa which can be seen at endoscopy and which
demonstrates intestinal metaplasia when biopsied [3].
The prevalence of BE in the general population varies
from 1.6 to 5.6% depending upon the group studied [4].
Gastroesophageal reflux disease (GERD) is a strong risk
factor for BE, and studies of subjects with chronic GERD
symptoms demonstrate a prevalence of BE ranging from
5 to 15% [4]. The amount of acid exposure correlates
with the risk and segment length of BE; other risk
factors for BE include age, sex and ethnicity [4].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adenocarcinoma with an average incidence rate at 0.5%
per year [4]. Increased segment length of BE (> 3 cm) is
associated with an increased risk of carcinoma compared
to short segment BE (< 3 cm) [3]. The development of
dysplasia in BE frequently precedes the development of
adenocarcinoma, with patients demonstrating a stepwise
progression from low grade dysplasia (LGD) to high grade
dysplasia (HGD), to intramucosal adenocarcinoma and
finally to adenocarcinoma. Patients who develop HGD
are at significantly increased risk for the development of
adenocarcinoma, with studies placing the incidence of
adenocarcinoma at between 5.6 to 6.6% per year [5].
Treatment for patients with BE consists of surveillance en-
doscopy and treatment of GERD, if present. Management
of patients with HGD is more controversial with three
possible strategies: surgical esophagogastrectomy, frequent
surveillance endoscopy or endoscopic therapy [4].
Despite the frequent endoscopic surveillance of pa-
tients with BE, reports of BE with a concurrent second
esophageal malignancies are rare; we report a case of an
80 year-old male who presented to our institution for
management of BE with HGD. Subsequent evaluation
demonstrated BE with HGD and a large nodule of melan-
oma invading into the submucosa. Our discussion reviews
the differences between primary and metastatic melanoma
of the esophagus and the rarity of collision tumors in
the esophagus. To our knowledge, this is the first case
in the English literature describing metastatic melanoma
occurring in conjunction with BE and is the first to
include molecular studies of the melanoma.
Case presentation
Case
An 80 year-old Caucasian male was referred to our institu-
tion in November 2011 for consideration of endoscopic
therapy of BE with high grade dysplasia. Previously,
the patient had underwent an endoscopy at an outsideFigure 1 Endoscopic images demonstrating the area of BE with noduinstitution which demonstrated long segment BE from
20 to 30 cm, two discrete linear ulcers from 25 to 22
cm and a tiny hyper-pigmented erosion in the cardia.
Esophageal biopsies at the outside institution demon-
strated Barrett esophagus with high-grade dysplasia.
At the time of endoscopy at our institution, there were
esophageal mucosal changes secondary to established
long segment BE extending from the upper extent of
the gastric folds which were 35 cm from the incisors
to the squamocolumnar junction, which was at 20 cm
from the incisors. Nodularity was present from 24 to
28 cm. Mucosal resection was performed with the
endoscopic resection within the BE limited to the area
of nodularity. The resection was performed with a
band ligation and snare resection technique (Duette
Kit, Cook Medical, Bloomington, IN) with a total of
four pieces resected (Figure 1a and b).
Microscopic examination of the resected tissue dem-
onstrated BE with HGD extending to the edge of the
specimen. No invasive adenocarcinoma was identified
(Figure 2a). Also present in one resected specimen
was a well circumscribed nodule of tumor cells involv-
ing the submucosa with overlying mucosal ulceration
(Figure 2b). A second, smaller nodule of tumor cells
with prominent intra-cytoplasmic pigment was present
in a separate section from the mucosal resection, in-
volving the muscularis mucosa. These latter tumor cells
were arranged in nests and demonstrated moderately
atypical nuclei with frequent prominent nucleoli, sur-
rounded by moderate amounts of eosinophilic cyto-
plasm (Figure 2c). Immunohistochemical stains were
performed and demonstrated that the tumor nodule
was negative for pan-cytokeratin and positive for S–100,
HMB 45, and Melan-A (Figure 2d-f respectively). These
findings were consistent with melanoma. A review of
the H&E stained sections did not demonstrate the pres-
ence of any melanoma in situ in the overlying mucosa,
which instead demonstrated high-grade dysplasia of BE.larity before (a) and after (b) resection.
Figure 2 Histological and immunohistochemical findings. a) Barrett esophagus with high grade dysplasia present in the patient’s resection
material (H&E, 100X). b) Second tumor nodule present within the mucosa and submucosa with distinct histologic features including c) large
epithelioid cells with atypical nuclei with prominent nucleoli and frequent mitotic activity (H&E, 40X; H&E, 400X respectively).
Immunohistochemical testing demonstrated the second tumor was positive for d) S-100, e) HMB-45 and f) Melan-A (each 40X).
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melanoma.
A subsequent PET scan demonstrated multiple areas
of uptake in the bone marrow and skull consistent with
widespread metastatic disease. Bilateral pleural effusions
were present, as well as a small focus of uptake in the
esophagus. Numerous lesions were identified in the liver
and spleen, consistent with metastatic disease.
Molecular studies were performed on formalin fixed par-
affin embedded tissue from the esophageal mucosal resec-
tion. Following tumor enrichment by macro-dissection of
an area containing approximately 85% melanoma nuclei,
molecular testing demonstrated the presence of a 1799T>A
(V600E) mutation in BRAF (Figure 3). No mutations
were found in exons 9, 11, 13, 17 and 18 of KIT. Due to
the side effects of BRAF inhibitors, it was believed the
patient would not benefit from this form of therapy.
After discussion about other potential palliative therapy,
the patient's family decided on hospice care.Figure 3 Pyrosequencing results demonstrate the presence of a 1799
shows a CAC>CTC change involving the second nucleotide position of cod
quantification reveals 68% mutant allele in the tumor sample. This nucleoti
acid position 600.Discussion
Melanoma of the esophagus is a rare entity, both in primary
and metastatic forms. Garfinkel provided one of the first re-
ports of primary melanoma of the esophagus in 1952 and
de la Pave et al. demonstrated the presence of melanocytes
in esophageal epithelium in a small number of autopsy pa-
tients with esophagitis in 1963, providing a possible explan-
ation for the development of primary melanomas in this
location [6,7]. Diagnostic criteria for primary melanoma of
the esophagus includes the presence of in-situ melanoma, a
radial growth phase, melanocytosis, and mixed epithelioid
and spindle cell morphology, in the context of no his-
tory of cutaneous melanoma [2,8]. Additionally, some
authors have suggested that metastases to other ana-
tomic sites or organs are important for distinguishing
between primary esophageal melanoma and metastatic
melanoma of the esophagus [2].
Collision tumors between BE and other malignancies are
relatively rare. There have been reports of adenocarcinomaT>A mutation in codon 600 of the BRAF gene. The pyrogram
on 600, highlighted in yellow, in the reverse strand. Allele
de change results in a valine to glutamic acid substitution at amino
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small cell carcinoma, and other primary neuroendocrine
tumors [9-11]. While there are existing case reports of
primary melanoma of the esophagus, our review of the
literature could only demonstrate two cases describing
melanoma of the esophagus occurring in a background of
BE. Both cases describe the melanoma as a primary lesion
[8,12]. In reviewing our case, the histology is most consist-
ent with metastatic melanoma rather than a primary lesion.
There is no evidence of melanoma in-situ in the overly-
ing mucosa, the tumor does not demonstrate a mixed
epithelioid and spindle cell morphology, and the patient
demonstrates the presence of additional metastatic lesions
involving the bone marrow, liver and spleen. While no pri-
mary cutaneous melanoma could be demonstrated on
physical exam, it may be that the primary melanoma has
regressed, particularly given the patient's age. Appropriate
immunohistochemical stains supported a diagnosis of
melanoma and demonstrated that the tumor was distinctly
different from the surrounding BE, which itself demon-
strated features of high-grade dysplasia.
As with many tumors, the advent of modern molecular
technology has greatly expanded our understanding of the
genomic and protein basis behind many tumors. The dis-
covery of constitutively activating mutations in the BRAF
and KIT genes in subsets of melanoma has expanded
treatment options to include specific molecularly targeted
kinase inhibitors such as vemurafinib and imatinib. The
V600E mutation in BRAF has now been associated with
approximately 80% of melanomas and seen predominantly
in melanomas arising on skin without chronic sun damage
[13,14]. Inhibition of mutated BRAF with targeted inhi-
bitor therapy such as vemurafinib has proven successful in
achieving complete or partial regression of tumors in
many patients, although resistance frequently develops
[15]. Our patient demonstrated a 1799T>A (V600E) muta-
tion in his tumor, providing secondary evidence that his
tumor most likely arose from a cutaneous lesion. No acti-
vating mutations were detected in the kinase, juxtamem-
brane or extracellular domains the KIT gene, consistent
with the observation that BRAF and KIT mutation are
associated with different subsets of melanoma and are
generally mutually exclusive [13].
Conclusions
In summary, we describe the first report of metastatic
melanoma of the esophagus arising in a background of
BE with molecular analysis for the presence of BRAF
and KIT mutations. Our report emphasizes the rarity of
the collision between a separate malignancy and BE and
demonstrates the utility of molecular studies both for
predictive value and, in the case of melanoma, for sup-
porting the conclusion of whether melanoma represents
a primary malignancy versus metastases.Consent
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